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SUMMARY POINTS
Advances in laboratory techniques have led to a rapidly increasing use of biomarkers in epidemiological studies.
Biomarkers of internal dose, early biological change, susceptibility and clinical outcomes are used as proxies for
investigating interactions between external and ⁄or endogenous agents and body components or processes. The
need for improved reporting of scientific research led to influential statements of recommendations such as the
STrengthening Reporting of OBservational studies in Epidemiology (STROBE) statement. The STROBE initiative
established in 2004 aimed to provide guidance on how to report observational research. Its guidelines provide a
user-friendly checklist of 22 items to be reported in epidemiological studies, with items specific to the three
main study designs: cohort studies, case–control studies and cross-sectional studies. The present STrengthen-
ing the Reporting of OBservational studies in Epidemiology –Molecular Epidemiology (STROBE-ME) initiative
builds on the STROBE statement implementing nine existing items of STROBE and providing 17 additional items
to the 22 items of STROBE checklist. The additions relate to the use of biomarkers in epidemiological studies,
concerning collection, handling and storage of biological samples; laboratory methods, validity and reliability of
biomarkers; specificities of study design; and ethical considerations. The STROBE-ME recommendations are
intended to complement the STROBE recommendations.
Eur J Clin Invest 2012; 42 (1): 1–16
Introduction
In recent years, advances in laboratory techniques have led to a
rapidly increasing use of biomarkers in epidemiological
studies, a field known as molecular epidemiology [1–5]. Biomar-
kers are any substance, structure or process that can be mea-
sured in biospecimens and may be associated with health-
related outcomes. Biomarkers of internal dose, of early biologi-
cal change and of susceptibility (see Fig. 1 and Box 1 for defini-
tions) are used as proxies for investigating the interplay
between external and ⁄or endogenous agents and the body.
Biomarkers may provide valuable scientific tools because of
This article is being simultaneously published in 2011 in PLoS Medicine,
Journal of Clinical Epidemiology, Preventive Medicine, Mutagenesis, Journal
of Epidemiology and Community Health, European Journal of Epidemiology
and European Journal of Clinical Investigation. Reproduced by permission
of the authors.
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their ability to inform biological mechanisms through the
examination of early, intermediate and late molecular and cel-
lular events. Moreover, a biomarker may capture several exter-
nal exposure variables in a single biologically relevant quantity,
provide quantitative measurements, increase statistical power
or be used as an efficient and informative intermediate out-
come. Finally, biomarkers can be used to identify susceptible
individuals and to improve diagnosis and early detection of
disease as well as prediction of major clinical outcomes in
patients with a given disease. Figure 1 describes the whole
spectrum of applications of biomarkers; the scheme uses cancer
as an example because this is the field in which the conceptual
framework of molecular epidemiology has had the greatest
development and numerous postulated potential applications;
however, similar concepts apply to many other fields.
Biomarker-based measurements are not, however, problem
free. As in classical biomedical and epidemiological research,
considering methodological issues concerning the design,
conduct, analysis and interpretation of the results is essential to
adequately address a research question [6]. In addition to the
usual problems of bias and confounding that affect all clinical
and epidemiological studies, particular issues when using
biomarkers include (i) validity and reliability of biomarker
measurements, (ii) special sources of bias, (iii) reverse causality
and (iv) false positives as a result of multiple testing or selective
reporting. To conceive relevant and valid studies, in biomarker-
based research, we need an in-depth understanding and
integration of methodological and substantive (i.e. biological,
clinical and environmental) knowledge. Complete, accurate
and transparent reporting of study design, methods, conduct
and findings is required to allow the study to be fairly and
adequately evaluated and summarized including avoidance of
selective reporting of positive results [7–10]. Empirical evidence
suggests that the results of the most highly cited biomarker
studies across medicine almost consistently report larger effect
estimates than those reported in subsequent meta-analyses [11].
Suboptimal reporting may also lead to inflated expectations on
the translational potential and clinical utility of findings [12].
At the other end of the spectrum, false negatives are also a
common problem [9], and they may result from limited
sample size, poor study design or inappropriate laboratory
assays [13].
The need for improved reporting of scientific research in
general led to influential statements of recommendations such
as CONSORT for randomized controlled trials [14,15] and
STrengthening Reporting of OBservational studies in
Epidemiology (STROBE) statement [16]. The STROBE initiative
was established in 2004 aiming at providing guidance on how to
report observational research. The resultant STROBE statement
was simultaneously published in several medical journals in
2007 [16,17]. Its guidelines provide a user-friendly checklist of
22 items to be reported in epidemiological studies, with items
specific to the three main study designs: cohort studies, case–
control studies and cross-sectional studies. The STROBE state-
ment has had an important impact. Its recommendations were
adopted by several journals, and there is evidence that they
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Figure 1 Schematic framework on the use of biomarkers in molecular epidemiology studies. Adapted from Vineis and Perera [42].
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have affected the style of result reporting [18]. However, there is
also evidence of misuse of the STROBE statement [19].
Recent advances in molecular biology and the vast amount
of data generated by high-throughput techniques (and conse-
quent changes and improvement in terms of epidemiology,
statistical analysis and study design) warrant implementing
the STROBE recommendations specifically for molecular epi-
demiology studies. For a review of the state of the art of molec-
ular epidemiology and the ensuing methodological problems,
see [1]. Molecular tools (biomarkers) are also increasingly
Box 1. Definitions of terms used in the text
There are several definitions of biomarkers. The most commonly adopted states that a biomarker is any substance or biological
structure that can be measured in the human body and may influence, explain or predict the incidence or outcome of disease
[24]. According to another definition, a biomarker is ‘a characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention’[43]. Biomarkers are
measured in human biospecimens typically using molecular, biochemical and cytogenetic techniques. Some investigators also
include under the biomarker umbrella measures derived from modern imaging techniques that aim to characterize biological
process, e.g. from positron emission tomography or functional magnetic resonance imaging. However, these biomarkers also
entail issues that are specific to image processing and interpretation that are beyond the scope of the guidance provided in this
manuscript. Some biomarkers (but not ‘exposure biomarkers’) allow insight into the cellular processes in the human body and
serve to explore the links among environmental ⁄ endogenous exposures, the genome, host factors ⁄ structures and disease. Based
on the concept that there is continuity between exposure to an external agent, its metabolism within the body and the onset of a
resulting time-delayed disease, we can distinguish three main types of biomarkers that are able to investigate the internal process
of interaction between the external agent and the body (Fig. 1).
A biomarker of exposure ⁄ internal dose is an indicator of current and ⁄or past exposure to environmental agents. Biomarkers
of internal dose may indicate, depending on their nature, a recent or very recent exposure as well as a long-term exposure. The
ideal biomarker of exposure is specific, detectable at very low concentrations, in quantitative relationship with the level of
exposure, and its levels integrate over time.
Metabolite concentrations change rapidly with a short half-life from a few hours up to a few days and may show a large daily
intra-individual variation as well as inter-individual variation. They may be specific for certain exposures or integrate several
types of exposure. For example, urinary 1-hydroxypyrene concentration is a surrogate for the measurement of complex PAH
exposure via different exposure routes, whereas urinary 4-(methylnitrosamino)-1-(3-pyridinyl)-1-butanol (NNAL), a metabolite
of 4-(methylnitrosamino)-1-(3-pyridinyl)-1-butanone (NNK), and its glucuronides are specific biomarkers of exposure to tobacco
smoke. A wide variety of highly sensitive analytical methods are used for the detection of parent compounds and their
metabolites in human biospecimens.
Biomarkers of early biological change are biomarkers that reflect the interaction between the external agent and the exposed
body. They usually encompass a broad and heterogeneous category; their main advantage is that their presence in subjects is
usually more frequent than the disease itself and they can be detected earlier, thus allowing researchers to identify potential
harm before a clinical disease manifests. Biomarkers of early biological change include markers of early detection of disease and
also prognostic markers if the outcome is death, recurrence or disability.
Biomarkers of susceptibility include multiple subcategories, which encompass both acquired (phenotypic) biomarkers and
genotypic markers [2]. Examples of the former are biomarkers of previous disease, whereas genotypic markers include the more
extensively studied category of inherited genetic variants. Concerning the latter, an essential issue is whether and how gene variants
manifest themselves in cellular functions and phenotypes and how they influence individual susceptibility to environmental
exposures. These include also cellular phenotypes (such as DNA repair capacity) applied to study differences in repair capacity in
healthy exposed populations [44]. There are ethnic and geographical differences in the frequency distribution of genetic variants.
Various technologies have been developed for low- and high-throughput genotyping. Additionally, markers of acquired susceptibil-
ity need to be considered, such as biomarkers of previous diseases or biomarkers of previous exposures such as epigenetic changes.
Biomarkers can also be used for the prediction of the clinical course and outcomes of disease under natural history or under
treatment. Although these clinical uses are usually outside the scope of traditional aetiological research, this is a very rapidly
expanding literature [45–47,23] with major challenges. Although the current recommendations could apply to these uses, for
tumour marker prognostic studies, the reader should refer to the REMARK guidelines [7].
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applied in epidemiology because of new and difficult issues
that are addressed, such as the effects of chronic low-level
exposures. While important discoveries of the past – such as
the role of cholesterol or tobacco smoking – originated from
studies with strong associations identified based on single
measurements, there is now a challenge to identify weaker
associations, and these require more accurate and sensitive
tools. This increases the importance of a meticulous,
comprehensive and transparent description of studies
involving biomarkers.
Herein, we propose an extension of STROBE, i.e. STROBE for
molecular epidemiology, STROBE-ME. The guidelines aim to
provide an easy-to-use checklist of items that authors may use
for reporting molecular epidemiology studies other than
genetic association studies.
Recommendations already exist for genetic association stud-
ies, a field that has specific characteristics and requirements of
reporting which have been included in a separate recent state-
ment (STREGA, an extension of STROBE) [20]. There is some
necessary overlap between the current guidelines and STREGA,
insofar as ‘susceptibility biomarkers’ are included in the pres-
ent recommendations. Communication of results of molecular
epidemiology studies is a still underdeveloped field. This paper
refers only to scientific communication of study results and
does not address the ethical problem of communicating results
to single individuals, see [21,22].
Aims and use of the STROBE-ME statement
The expected outcome of the present recommendations is an
improvement in the reporting of results, such that the edi-
tors, reviewers of papers and the readers understand better
what was actually done by the authors. STROBE-ME is
expected to lead to more organized and transparent papers
and to a better understanding of both the strengths and
weaknesses of the studies in molecular epidemiology. Our
recommendations do not dictate how studies should be
performed nor do they serve as a basis to evaluate the qual-
ity of observational studies; they only try to help improve
the reporting of research. The adoption of improved report-
ing standards may nevertheless have also an indirect benefit
on the quality of study design.
The parent STROBE statement is a checklist of 22 items to be
addressed when observational epidemiological studies are
reported. The STROBE items cover different aspects of report-
ing a study: the title (one item), introduction (two items), meth-
ods (nine items), results (five items), discussion (four items)
and funding of research (one item) [16]. The explanation and
elaboration document of STROBE [17] explains these items in
detail and provides good real-life examples in published works
for their application.
The statement proposed here is intended to be an extension
of the STROBE statement for molecular epidemiology studies.
The present recommendations are intended only for those stud-
ies in which biomarkers are used as an explanatory variable;
these include biomarkers of exposure ⁄ internal dose, biomar-
kers of early biological change and biomarkers of susceptibility
(Box 1, and Fig. 1). This set of biomarkers is used as measurable
proxy for the process of the interaction between an exter-
nal ⁄ endogenous agent and the body at different biological lev-
els. Other study designs involving biomarkers are not covered
by the present recommendations, including transitional studies
of validation and reliability of measurement.
Some items belonging to the original STROBE checklist have
been implemented for molecular epidemiology studies; other
items have been added de novo to the original checklist. The 10
implemented items include issues on study design specificities
in molecular epidemiology studies; description of relevant
participant conditions at the time of sample collection; and
particular statistical aspects if the biomarker measurements are
introduced into statistical models. The seven new specific items
added to the original STROBE checklist include biological
sample collection, storage and processing; and the laboratory
methods used for the analyses. The present extended checklist
was developed as an extension of the STROBE checklist
(Table 1). The recommendations are intended to complement
the existing STROBE guidelines, not to replace them; therefore,
all previously described items concerning observational studies
such as cohort, case–control and cross-sectional studies apply
to molecular epidemiological studies (when appropriate).
The present statement contains a checklist of items for report-
ing molecular epidemiology studies (Table 1); some explana-
tory text referring to single item description; and some Boxes in
which specific aspects of molecular epidemiology are briefly
addressed for readers’ reference. Although the current recom-
mendations could apply also to biomarkers used for the predic-
tion of clinical course and outcomes of disease, for tumour
marker prognostic studies the reader should refer to the
REMARK guidelines [7].
Concerning the uses of the present statement, additional
details on how the parent STROBE statement was used can be
found on the website (http://www.strobe-statement.org/). It is
expected that the statement will be adopted and referred to by
journals that publish molecular epidemiology papers, as well
as by journals that publish clinical research in which
biomarkers have an important role [23].
Development of the STROBE-ME statement
Amultidisciplinary group of epidemiologists, biostatisticians
and laboratory scientists (overall approximately 15 scientists)
developed the current recommendations. Also, editors of
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Table 1 The STrengthening in Reporting OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME)
Reporting Recommendations: Extended from STROBE statement
Item
Item
number STROBE Guidelines
Extension for Molecular Epidemiology
Studies (STROBE-ME)
Title and abstract 1 (a) Indicate the design of the study with a
commonly used term in the title or the abstract
ME-1 State the use of specific biomarker(s) in the title
and ⁄or in the abstract if they contribute substantially to
the findings
(b) Provide in the abstract an informative and
balanced summary of what was done and what
was found
Introduction
Background
rationale
2 Explain the scientific background and rationale for
the investigation being reported
ME-2 Explain in the scientific background of the paper
how ⁄why the specific biomarker(s) have been chosen,
potentially among many others (e.g. others are studied
but reported elsewhere or not studied at all)
Objectives 3 State specific objectives, including any
pre-specified hypotheses
ME-3 A priori hypothesis: if one or more biomarkers are
used as proxy measures, state the a priori hypothesis on
the expected values of the biomarker(s)
Methods
Study design 4 Present key elements of study design early in
the paper
ME-4 Describe the special study designs for molecular
epidemiology (in particular, nested case ⁄ control and
case ⁄ cohort) and how they were implemented
Biological
sample
collection
ME-4Æ1 Report on the setting of the biological sample
collection; amount of sample; nature of collecting
procedures; participant conditions; time between
sample collection and relevant clinical or physiological
endpoints
Biological
sample
storage
ME-4Æ2 Describe sample processing (centrifugation,
timing, additives, etc.)
Biological
sample
processing
ME-4Æ3 Describe sample storage until biomarker analysis
(storage, thawing, manipulation, etc.)
Biomarker
biochemical
characteristics
ME-4Æ4 Report the half-life of the biomarker and chemical
and physical characteristics (e.g. solubility)
Setting 5 Describe the setting, locations and relevant
dates, including periods of recruitment,
exposure, follow-up and data collection
Participants 6 (a) Cohort study – Give the eligibility criteria and
the sources and methods of selection of
participants. Describe methods of follow-up
Case–control study – Give the eligibility criteria and
the sources and methods of case ascertainment
and control selection. Give the rationale for the
choice of cases and controls
Cross-sectional study – Give the eligibility criteria
and the sources and methods of selection of
participants
ME-6 Report any habit, clinical condition, physiological
factor or working or living condition that might affect the
characteristics or concentrations of the biomarker
European Journal of Clinical Investigation Vol 42 5
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Table 1 Continued
Item
Item
number STROBE Guidelines
Extension for Molecular Epidemiology
Studies (STROBE-ME)
(b) Cohort study – For matched studies, give
matching criteria and number of exposed and
unexposed
Case–control study – For matched studies,
give matching criteria and the number of controls
per case
Variables 7 Clearly define all outcomes, exposures, predictors,
potential confounders and effect modifiers. Give
diagnostic criteria, if applicable
Data source ⁄
measurement
8 For each variable of interest, give sources of data
and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than
one group
ME-8 Laboratory methods: report type of assay
used, detection limit, quantity of biological sample used,
outliers, timing in the assay procedures (when
applicable) and calibration procedures or any
standard used
Bias 9 Describe any efforts to address potential sources
of bias
Study size 10 Explain how the study size was arrived at
Quantitative
variables
11 Explain how quantitative variables were handled
in the analyses. If applicable, describe which
groupings were chosen and why
Statistical
methods
12 (a) Describe all statistical methods, including
those used to control for confounding
ME-12 Describe how biomarkers were introduced into
statistical models
(b) Describe any methods used to examine
subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study – If applicable, explain how loss
to follow-up was addressed
Case–control study – If applicable, explain how
matching of cases and controls was addressed
Cross-sectional study – If applicable, describe
analytical methods taking account of sampling
strategy
(e) Describe any sensitivity analyses
Validity ⁄ reliability
of measurement
and internal ⁄
external
validation
ME-12Æ1 Report on the validity and reliability of
measurement of the biomarker(s) coming from the
literature and any internal or external validation used
in the study
Results
Participants 13 (a) Report the numbers of individuals at each
stage of the study – e.g. numbers potentially
eligible, examined for eligibility, confirmed
eligible, included in the study, completing
follow-up and analysed
ME-13 Give reason for loss of biological samples at each
stage
(b) Give reasons for nonparticipation at each stage
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Table 1 Continued
Item
Item
number STROBE Guidelines
Extension for Molecular Epidemiology
Studies (STROBE-ME)
(c) Consider use of a flow diagram
Descriptive data 14 (a) Give characteristics of study participants
(e.g. demographic, clinical and social) and
information on exposures and potential
confounders
(b) Indicate the number of participants with
missing data for each variable of interest
(c) Cohort study – Summarize follow-up time
(e.g. average and total amount)
Distribution of
biomarker
measurement
ME-14Æ1 Give the distribution of the biomarker
measurement (including mean, median, range and
variance)
Outcome data 15 Cohort study – Report numbers of outcome events
or summary measures over time
Case–control study – Report numbers in each
exposure category or summary measures of
exposure
Cross-sectional study – Report numbers of
outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their
precision (e.g. 95% confidence interval). Make
clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous
variables were categorized
(c) If relevant, consider translating estimates of
relative risk into absolute risk for a meaningful time
period
Other analyses 17 Report other analyses done – e.g. analyses of
subgroups and interactions and sensitivity
analyses
Discussion
Key results 18 Summarize key results with reference to study
objectives
Limitations 19 Discuss limitations of the study, taking into
account sources of potential bias or imprecision.
Discuss both direction and magnitude of any
potential bias
ME-19 Describe main limitations in laboratory
procedures
Interpretation 20 Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of
analyses, results from similar studies and other
relevant evidence
ME-20 Give an interpretation of results in terms of
a priori biological plausibility
Generalizability 21 Discuss the generalizability (external validity) of
the study results
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several specialist journals were involved from the outset. The
group met twice in London (UK) in 2008 and 2009, once in
Turin (Italy) in 2009 and once in Ło´dz´ (Poland) in 2010; it
sought external opinions from partners of the Environmental
Cancer Risk, Nutrition, and Individual Susceptibility (ECNIS)
European Network of Excellence – which was the initiator of
the STROBE-ME initiative. Overall, the process lasted 3 years.
While no formal process such as a Delphi consultation was
used for development, consensus was built by circulating sev-
eral versions of the statement within the group of developers
and an external circle of potential users. In all, over 30 scientists
were involved in the process.
Checklist of items
The items that should be considered when reporting molecular
epidemiology studies are shown in Table 1. These items are similar
to those that were originally recommended in STROBE, however,
with modifications that are specific to molecular epidemiology.
Later, we give a detailed description of each item. The purpose is
not to suggest how to set up a research project but how to improve
reporting of the research to allow readers (and reviewers) to better
understand what was actually done by the researchers.
ME-1 – State the use of biomarker(s) in the title
and ⁄or in the abstract if they contribute substantially
to the findings
When one or more biomarkers are measured in an
epidemiological study, it may be more informative reporting
this in the title or at least in the abstract of the article. This helps
the reader to identify immediately molecular epidemiology
studies and ensures a correct indexing in electronic databases.
ME-2 – Explain in the scientific background of the
paper how ⁄why the specific biomarker(s) have been
chosen, potentially among many others
The process leading to the choice of one or more specific bio-
markers for inclusion in a paper should be made clear in the
Introduction. Background information and rationale for the
choice of the specific biomarker(s) should be explicitly stated;
also, how the biomarker is introduced in the study design
should be made explicit (biomarker of exposure, internal dose,
early biological change and susceptibility). It should also be
clarified whether the biomarker is used as a proxy, and if so,
what it is intended to be a proxy for.
ME-3 – A priori hypothesis: if one or more biomarkers
are used as proxy measures, state the a priori hypoth-
esis on the expected values of the biomarker(s)
When stating the objective(s) of a study according to the
STROBE guidelines [16], it might be helpful to state explic-
itly the a priori hypothesis on the expected values of the
biomarker(s).
ME-4 – Describe the special study designs for
molecular epidemiology (in particular nested
case–control and case–cohort) and how they were
implemented
Study design details should be reported in the Methods sec-
tion. For traditional designs such as case–control, cohort and
cross-sectional studies, the STROBE recommendations can be
followed, with extra care in reporting the biological sample
collection integration within study design; for nested case–con-
trol and case–cohort studies, selection criteria for cases and
controls, sampling frame and matching criteria should be
reported with extra care, as they represent a main potential
source of bias in these study designs (see Box 2). In addition to
matching criteria for individuals, all methods used for select-
ing or matching biological samples (i.e. by storage time and by
batch) should be reported. Also, it is recommended to describe
briefly the cohort in which nested studies were implemented,
in terms of description of the population, sampling, outcome
ascertainment, follow-up period, number of subjects lost to
follow-up and primary objective for which the cohort was
established.
Table 1 Continued
Item
Item
number STROBE Guidelines
Extension for Molecular Epidemiology
Studies (STROBE-ME)
Other information
Funding 22 Give the source of funding and the role of the
funders for the present study and, if applicable,
for the original study on which the present article
is based
Ethics ME-22Æ1 Describe informed consent and approval from
ethical committee(s). Specify whether samples were
anonymous, anonymized or identifiable
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ME-4Æ1 – Report on the setting of the biological sam-
ple collection; amount of sample; nature of collecting
procedures; participant conditions; time between
sample collection and relevant clinical or
physiological endpoints
An accurate description of the sample collection and shipment
is necessary to enable the reader to evaluate potential sources
of bias or errors in the biomarker measurement and for
ensuring an appropriate reproducibility of the scientific experi-
ment (see Box 3). The following items should be reported: (i)
the setting of the biological sample collection (place, time of the
day, time of the year, laboratories involved, personnel
involved, etc.); (ii) amount ⁄volume ⁄ size of sample(s); (iii) nat-
ure of the collecting procedure (anticoagulant involved, e.g.
heparin, EDTA) (iv) if the participant is healthy, participant
condition at the sample collection (fasting status, position, etc.)
when appropriate; (v) if participants are not healthy individu-
als in stable physiological conditions, then report the relevant
aspects of the health status and clinical conditions of the
participants [24,25]; (vi) in all instances, consider reporting the
time between sample collection and relevant clinical or physio-
logical endpoints that might have affected the characteristics or
concentrations of the biomarker [26]. In particular, report any
relevant characteristic of the participants, which might influ-
ence the biomarker levels in any known or unknown way. For
example, position of the study subjects, such as orthostatism
decreases plasma volume, so that proteins and cholesterol lev-
els can be lowered by 5–15% relative to the supine position.
Detailed information on all critical steps that might have
altered the biological samples or influenced the final biomarker
measurement should be identified and reported accordingly in
the Methods section.
ME-4Æ2 – Describe sample processing (centrifugation,
timing, additives, etc.)
A comprehensive description of all steps of sample processing
is needed in the Methods section to assess experimental repro-
ducibility. This description ranges from manual handling of
Box 2. Specificities of study design for molecular epidemiology: nested case–control studies and
case–cohort studies
Molecular epidemiology uses the same study designs as the general epidemiology, but some variants are more common. In par-
ticular, case–control studies nested in cohorts and case–cohort studies are frequently used to avoid extensive and costly measure-
ments in large cohorts. In nested case–control studies derived from established cohorts, controls are usually matched for age and
sex, and also for time variables related to sample collection and disease onset. The method of control selection in these studies is
‘incidence density’ sampling, and an incidence risk ratio is estimated. Controls may develop the disease of interest subsequently
to the diagnosis of the case, but they represent the cohort set at risk of developing the disease when each case occurs [24]. The cri-
teria for case inclusion and control matching and selection and their rationale should be reported [1].
In case–cohort studies, unmatched controls come from a sample of the cohort at inception without being matched to cases on
time to outcome. The method for control selection in these studies is based only on the population at baseline, without regard to
failure times, and a risk ratio is estimated [24,1].
Both study designs share the important feature that cases and controls come from the same cohort study: recall bias is not of
concern if exposure assessment was carried out before disease onset; nonparticipation bias is avoided because rapidly fatal cases
have the same probability of inclusion as others; and reverse causation becomes less likely as biological samples were collected
before the onset of the clinically documented disease. The nested case–control study tends to be more efficient than the case–
cohort study in selecting controls to address confounding. In case–cohort studies, however, the same sample of controls can be
compared to different samples of cases (thus different outcomes can be studied). Also, as the subcohort is a random sample of the
whole cohort, prevalence of exposure can be estimated and external comparisons can be made.
The main concerns regarding nested case–control studies are that controls are not representative of the cohort population and
they have few other uses, so the investment in biomarker analyses cannot be leveraged for other research. On the other hand,
case–cohort studies rely on the assumption that exposure can be equally well measured in the subcohort as in the cases. How-
ever, three issues regarding biomarker validity make this assumption questionable: batch effects, the storage effect and freeze–
thaw cycles. There are technological and staffing limits to how many samples can be analysed in one go so samples are run in
batches or groups. Conditions of the analyses should not vary by batch, but it is clear that for many biomarker measurements
this is not true, i.e. there are substantial batch effects (laboratory variation). Also, not all biomarker targets are stable at the usual
storage temperature ()80 C), and when samples freeze and thaw, the pH and ionic balance of the liquid phase of the sample can
be very different from the natural condition of the sample. Changes in pH and ionic balance can degrade biomarker targets. For
these reasons, it may be necessary to include matching by length of storage, batch and freeze–thaw cycles [1].
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samples to specific machinery used for laboratory processing
(see Box 3). When a well-established technique is used, the
main process can be referred to by quoting the article where the
technique is described and any variation from the initially
described laboratory technique should be explicitly stated.
ME-4Æ3 – Describe sample storage until biomarker
analysis (storage, thawing, manipulation, etc.)
Particularly in nested case–control and case–cohort studies,
biomarkers can be measured in biological samples stored for
extended durations; sometimes, samples may have already
undergone freeze–thaw cycles. As these processes can par-
tially alter the biomarker values under examination, it is
important to report in the Methods section any manipulation
that the biological samples may have undergone, together
with a detailed description of how the samples were stored.
ME-4Æ4 – Report the half-life of the biomarker and
chemical and physical characteristics
(e.g. solubility)
For new biomarker(s) only, some basic biochemical information
relevant to the interpretation of the measured values should be
reported in the Methods section. This includes biochemical and
biophysical characteristics that might be relevant when inter-
preting the results, such as half-life, solubility or lipophilicity.
ME-6 – Report any habit, clinical condition,
physiological factor, or working or living condition
that might affect the characteristics or
concentrations of the biomarker
Report any relevant characteristic of the participants, which
might influence the biomarker levels in any known or unknown
way [24]. For example, exposure to air pollution [27] or season-
ality [28] might influence DNA adduct levels in healthy
subjects; similarly, type of diet [29,30] or amount of sunlight
exposure [28,31] might influence DNA damage biomarkers in
healthy subjects.
ME-8 – Laboratory methods: report type of assay
used, detection limit, quantity of biological sample
used, outliers, timing in the assay procedures (when
applicable) and calibration procedures or any
standard used
The methods used in the laboratory for biomarker analyses
should be described in detail in a dedicated section of the
Methods. Particular care should be taken to describe new or
Box 3. Collection, handling and storage of biological samples
Several types of human biospecimens can be collected for carrying out molecular epidemiology studies. Blood samples may be
stored as a whole or separated into subfractions and blood components (red blood cells, serum, plasma, buffy coat and white
blood cell subfractions). White blood cells contained in the buffy coat are the most widely used source of DNA. Urine can be used
as a solution of excreted parent compounds and metabolites to be measured, or as a source of exfoliated cells of the urinary tract.
Collection and primary processing are performed accordingly. Other human tissue specimens used in molecular epidemiology
studies include body fluids (i.e. cerebrospinal fluids), cell washes (i.e. buccal wash or swabs), epithelial smears, surgical material, nails
and hair. Each step in collection, storage, thawing, manipulation and laboratory analysis can introduce errors that may lead to
bias and variability. Random error, if evenly distributed in study subgroups, is likely to attenuate or eliminate differences.
Systematic errors (e.g. differential clinical conditions, handling or storage of biological samples from cases and noncases) may
generate spurious associations.
Timing of collection often influences the true biomarker level. For example, hormones have hourly, daily or monthly cycles.
Prolonged venipuncture can induce release of prolactin or increase white blood cell counts. A very narrow needle causes haemol-
ysis. Several additives can be added to blood, e.g. metaphosphoric acid for vitamin C; anticoagulants such as heparin, EDTA or
citrate are needed for plasma collection (i.e. not needed if only serum is collected). There may be disadvantages: heparin binds to
many proteins and influences T-cell proliferation; EDTA interferes with cytogenetic analyses. Citrate-stabilized blood affords
better quality of RNA and DNA than other anticoagulants. Other additives include protease inhibitors and RNAse inhibitors to
avoid degradation of proteins and RNA, respectively.
The goals of a proper sample storage are to ensure (i) standardized procedures for all phases; (ii) minimal loss or degrading of
material (e.g. because of malfunctioning of freezers); (iii) optimal preservation of material; (iv) blinding, whenever appropriate;
(v) easy access to the material when needed; (vi) easy matching of biological material with individual identity; (vii) respect of
confidentiality; and (viii) anticipation of emergencies. Stability of the compounds to be measured depends on the type of mea-
surement and temperature of storage: for example, fatty acids should be measured within 2 weeks when samples are stored at
4 C, within a few months when stored at )20 C, up to one year when stored at )80 C. A few studies have been conducted on
the stability of different analytes, but the literature is far from being exhaustive.
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modified techniques, while for a well-established technique,
the main process can be referred to by quoting the article where
the technique is described, and any variation from the initially
described laboratory technique should be explicitly stated. Any
calibration procedures or external standards used in the labora-
tory (or for comparing data coming from different laboratories)
should also be described. The definition of ‘outlier’ should be
clearly given (for example, whether it is based on pathophysio-
logical, technical or statistical grounds).
ME-12 – Describe how biomarkers were introduced
into statistical models
Usually, statistical methods that apply to biomarkers do not
differ from those used in other branches of epidemiology and
clinical research. Here, we mainly refer to specificities of bio-
marker research. When continuous variables are used (a very
common occurrence for biomarkers), testing for linearity may
be useful when the marker is used as a covariate, in addition
to checking other statistical model assumptions when it is used
as an outcome. Statistical manipulation of a variable derived
from biomarker measurement values should be described in
detail as for other variables included in the statistical models.
Whether the variable is introduced as a continuous or categori-
cal variable (and if categorical what criterion has been used for
identifying cut-off points); whether extreme values have been
excluded, and with which criteria; whether the original
variable has been log transformed or manipulated in any other
way; whether crude measurements or corrected ⁄ adjusted val-
ues (e.g. ratios to binding hormones and creatinine-adjusted
values) were analysed; and how samples with nondetectable
biomarker levels were dealt with (e.g. considered as zero, as
the detection limit, as half of that level or imputed) should be
clearly stated.
ME-12Æ1 – Report on the validity and reliability of
measurement of the biomarker(s) coming from the
literature and any internal or external validation used
in the study
Validity and reliability of biomarker(s) measurement should
be reported when every specific biomarker is introduced (see
Box 4). Measurement error has several components, and there
is ambiguity on the use of the term, because ‘error’
encompasses both true ‘variations’ and ‘mistakes’. ‘Analytical’
measurement errors originate from the laboratory tech-
nique(s), including between-batch variation, while other
sources of ‘pre-analytical error’ include variations in the indi-
viduals or the samples that are investigated [1]. Ideally, the
inter-individual, intra-individual and inter-laboratory varia-
tions should be reported for each biomarker to enable the
reader to understand the potential source of error for each
specific biomarker. Literature-based reliability estimates
should be properly referenced. When these figures are not
available from the literature, this should also be stated. If
aspects of the validity and reliability have been determined as
part of the current study, the methods and process should be
briefly stated. When a specific laboratory procedure or method
for biomarker measurement has been standardized across
laboratories for facilitating the comparability, this should be
clearly stated [32,33].
Biomarker measurement validation is particularly important
when a new biomarker is described. Without information on
measurement error, intra-individual variation and inter-indi-
vidual variation biomarker studies are uninterpretable. Also,
variation by batch is usually very relevant and may create
artifactual relationships [34]. For more detailed presentation of
validity and reliability issues, see Box 4.
Besides validity and reliability of biomarker measurements,
it is increasingly recognized that the study results are likely to
be more credible when they have been reproduced by some
additional validation process, either internally (e.g. by cross-
validation) or preferably with external independent validation
in samples that are totally different from those where the bio-
marker was first tested [35]. All attempts at internal and exter-
nal validation carried out by the authors should be reported in
detail in the Methods section, and the respective results should
be shown in the Results section.
ME-13 – Give reasons for the loss of biological
samples at each stage
Loss of specimens, nonevaluable samples (because of poor
quality) or assay failures are common occurrences. When some
samples are not included in the final analysis because of prob-
lems in sample quality, quantity, availability, timing of sample
collection or technical failure give detailed reasons. This will
help in tracking the final sample size and the reasons for
sample exclusions.
ME-14Æ1 – Give the distribution of the biomarker
measurement (including mean, median, range and
variance)
An appropriate description of the biomarker measurement dis-
tribution is of help for interpreting results and for comparing
similar biomarker measurements by other scientists. It also
often facilitates the biological interpretation of the results. A
graph of the full distribution may be useful (when relevant, also
by exposure status or case ⁄ control status).
ME-19 – Describe main limitations in laboratory
procedures
Potential and actual limitations met in laboratory procedures
should be described in detail in the Discussion. It may be
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Box 4. Biomarker validity and reliability
To achieve an accurate estimate of the association between biomarker and a disease, reliable and valid measurements of expo-
sure, covariates (potential confounders and effect modifiers) and outcomes are needed [48]. Validity is defined as the (relative)
lack of systematic measurement error when comparing the actual observation with a standard, which is a reference method
representing the ‘truth’. While validity entails a ‘standard’, reliability (reproducibility and repeatability) concerns the extent to
which any measuring procedure yields the same results in repeated experiments [49].
Validity and reliability are separate entities: a measurement may be perfectly reliable (reproducible in different laboratories
and repeatable at different times), but consistently wrong, i.e. far away from the true value; conversely, another one can be
unbiased on average, but unreliable if the measurements scatter widely around a true value. Both validity and reliability are
important; however, as validity is often not measurable, reliability is sometimes used (incorrectly) as a surrogate.
Timing is also a relevant aspect: inferences about the meaning of biomarker measures are often strictly time specific, as time
influences the results in several different ways [49]. For example, while DNA genetic variants are the same for each individual
through one’s life time, their epigenetic profile may change markedly over time.
Biomarker variability influences associations with the endpoint, thus needs to be assessed and reported upon. A single
measure of a biomarker for one individual will be affected by (i) variability within subject (intra-subject); (ii) biological sample
variation (i.e. variation depending on the frame of biological sample collection); and (iii) laboratory variation.
Intra-individual variation is sometimes so large that between-individual variation (usually the unit of interest) is hard to
detect. A single biological measurement (assume that this is in the absence of laboratory variation) represents the biomarker
level ⁄ status at a particular time. The biomarker may undergo diurnal, monthly, seasonal or longer variations, e.g. prolactin has a
circadian rhythm, oestrogens vary through the menstrual cycle, biomarkers related to recent fruit and vegetable intakes may
have seasonal variations. Other biomarkers are more stable, i.e. have less intra-individual variation, and thus, a single mea-
sure ⁄ sample is usually sufficient (such as mercury in hair, SNPs – single nucleotide polymorphisms). Variation in exposure to
other compounds may have influence on the marker level. Intra-individual variability can be measured only if repeated samples
from the same individual are collected [50]. Depending on the research question, a measure of a recent, short-term or instanta-
neous level may be desired (e.g. current CD4 count in a HIV patient), or an average level over a specified time interval (e.g. usual
vitamin D level).
Biological sampling variation is related to the circumstances of biological sample collection. For example, hyperproliferation of
colonic cells is extremely variable at different segments of the colon mucosa. Therefore, not only the intra-subject variation over
time is important, because of the varying exposure to agents that induce cell proliferation, but also the measurements are
strongly influenced by how and where the mucosa is sampled from.
Laboratory measurements can have many sources of error, in particular two general classes of laboratory errors: those that
occur between analytical batches and those that occur within the batches. Handling, processing and storing of specimens may
contribute to errors. Laboratory procedures need to be in place to minimize such variation and avoid biases. Quality control
procedures such as the inclusion of laboratory quality control samples and blinded split samples are used to assess the extent of
these errors. There should be no identifiers that relate the sample to any other characteristics of the individual from whom it
came and in particular of their disease status or any other factor.
The errors of biomarker measurement may have different impact depending on their error distribution. If the epidemiological
study has been conducted blindly, i.e. the laboratory analyses have been carried out with no knowledge of the exposed ⁄unex-
posed or diseased ⁄healthy status of the subjects, the measurement error is expected to be evenly distributed across strata of
exposure or disease. However, this is true only if the error is equally distributed across the scale of the exposure. This kind of
misclassification leads to underestimation of the risk ratio because of a ‘blurring’ of the relationship between exposure and
disease. Both underestimation and overestimation of the association of interest may occur when misclassification is not evenly
distributed across the study variables [51]. Individuals with extreme biomarker levels may be excluded, or sensitivity analyses
are carried out with and without them to check whether they overly influence the general findings.
The most important single measure of biomarker reliability is the intra-class correlation coefficient (ICC). This is a quantitative
measurement of the between-person variance divided by the total (between- plus within-subject) variance [52]. It describes how
strongly measurements taken in the same subject resemble each other in comparison with the inter-individual variance.
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helpful also to report whether the limitation would likely have
introduced a random or systematic error and, if systematic, to
suggest in which direction this might have biased the results.
Validation of results of biomarker studies is of major
importance, and the discussion should address whether any
validation procedure was used in the study [36].
ME-20 – Give an interpretation of results in terms of a
priori biological plausibility
Results should be interpreted in the light of the mechanism(s)
of action of the biomarker(s) and of the a priori hypothesis,
thus offering a biologically plausible interpretation. It may be
useful to stress the added value of the biomarker(s) in expli-
cating the biological mechanism underlying the association
reported.
ME-22Æ1 – Describe informed consent and
approval from ethical committee(s). Specify
whether samples were anonymous, anonymized or
identifiable
Molecular epidemiology poses special ethical issues that are
summarized in Box 5.
Box 5. Ethical considerations
Legal issues related to the use of stored human biological material are contained in a European guideline issued by the Council of
Europe (http://www.coe.int). In the United States, a useful website is http://nih.gov/sigs/bioethics. When incorporating bio-
specimen-derived measurements, the following requirements should be met: follow respectful protocols in eliciting information;
avoid harm to participants; secure proper informed consent, manage anonymization of interlinking databases; establish confi-
dentiality and security safeguards; develop proper responses to requests for personal data by various parties; devise sound data
access, ownership and intellectual property policies; be clear about whether and how individuals will be informed of findings
that might be medically helpful for them; and arrange supervision by research ethics and privacy protection bodies [53].
Clearly, each of these requirements would need extensive comments. In particular, how ‘broad’ should the consent be? On the
one hand, a broad consent (e.g. ‘the biological samples will be used for the identification of gene variants that may predispose to
chronic diseases’) implies a greater freedom of the researcher, who is not obliged to collect further consent forms each time a new
gene is investigated. On the other hand, such a generic informed consent form explains very little to the recruitees.
The concept of informed consent was initially formulated in the Declaration of Helsinki in 1964, with the latest revision in 2000
(http://www.wma.net). Recent developments in molecular epidemiology tend to overcome the conflict between ‘broad’ and
‘narrow’ consent forms, introducing the idea of a ‘two-level consent’, i.e. a relatively broad procedure at first, followed by a more
specific and detailed approach when studies on single genes ⁄biomarkers are conducted.
For example, there is a broad agreement that low-penetrant variants that are common in the general population and are associ-
ated with a slight increase in the risk (interacting with environmental exposures) should not be subject to strict rules as far as
ethical implications are concerned. In fact, knowledge of presence or absence of a single allele involved in metabolic pathways
neither allows the carrier to modify her ⁄his risk profile substantially nor allows the researcher to identify other members of the
family, which would violate confidentiality. The case of highly penetrant gene variants is different: e.g., the identification of the
carrier of a rare mutation allows the researchers to identify other family members possibly affected, with potential detrimental
effects (e.g. on insurance policies).
The same reasoning applies to biomarkers. The majority of biomarkers used in observational epidemiological research are of
little utility to the subjects participating in the research, when taken alone. This is particularly true for the biomarkers of expo-
sure, but also some biomarkers of early biological change ⁄ effect may not be meaningful when extrapolated from the research
context; for example, DNA adduct level is difficult to interpret at a personal level. Researchers should have a clear view of the
practical implications of testing for the study subjects, and in particular what to do in each of these situations: when no effective
treatment is possible; when treatment is available with close balance of favourable ⁄unfavourable effects; and effective treatment
is available with scarce unfavourable effects. Similar considerations apply to biomarkers, which can be weakly or strongly
associated with diseases and less or more associated with family history.
Anonymization of information is another difficult issue. First, there is a problem of definitions: ‘‘‘identifiable’ is a sample with
name or social security number on it; ‘coded’ is a sample with a code that allows relatively easy identification of the person;
‘encrypted’ is a sample with a code that does not allow easy identification of the person, but this is possible with extra effort;
finally, ‘anonymous’ is a sample for which there is no possibility of linking to a person. Clearly, a really anonymous collection of
samples is of very little use for epidemiological research, which is based on follow-up and linkage of laboratory data and health-
related data.
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Discussion
Transparent reporting is essential in epidemiology as in science
in general, and in molecular epidemiology in particular. Given
that the use of biomarkers has raised great expectations in terms
of potential elucidation of disease aetiology and pathogenesis,
it is important to raise awareness on the intrinsic limitations of
biomarker measurements. In particular, measurement error is a
common problem and can cause both false-negative and false-
positive results [9]. Also, the lack of a formal study design
may substantially impair the interpretation of the results, and
selective reporting of results can be detrimental.
The present STROBE-ME checklist should strengthen primar-
ily the reporting and interpretability of molecular epidemiology
studies, if used widely and systematically. It has been devel-
oped based on two strong foundations: (i) the well-established
STROBE collaboration and the related statement and (ii) an
ECNIS working group formed by epidemiologists, biostatisti-
cians and laboratory scientists with extensive experience in the
field of molecular epidemiology and biomarker analyses.
We hope that these guidelines will improve the quality of
reporting of molecular epidemiology and other biomarker-
based research, including studies conducted within the
growing number of biobanks and of biomonitoring projects.
The ethical duty of researchers includes reporting findings with
accuracy, completeness and transparency, and in sufficient
detail to allow the scientific community to consider them ade-
quately, assess their strengths and weaknesses and make fair
comparisons. Well-reported published studies can contribute to
and be summarized with an evidence-based approach in an
appropriate manner (i.e. on sound scientific grounds) to arrive
at unbiased conclusions that lead to better knowledge and the
advancement of citizens’ health [37,38].
Finally, we would like to stress that these recommendations,
as the original STROBE statement and other guidelines on
reporting research [7,14,16,20], are evolving documents requir-
ing continuous feedback, reassessment and refinement. The
STROBE-ME guidelines will be published on the STROBE web-
site (http://www.strobe-statement.org) where a forum for dis-
cussion and improvement of the checklist and related material
will be available.
Guidance documents should also be appraised for their even-
tual impact. The EQUATOR initiative [39–41] has found that
only 17% of the surveyed guideline developers performed a
formal evaluation of the impact. We will engage journal editors
in attempts to evaluate the impact of the present statement in
the long run.
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